Phillip A. Sharp's most recent trade in Alnylam Pharmaceuticals Inc was a trade of 11,250 Common Stock done at an average price of $131.2 . Disclosure was reported to the exchange on Jan. 23, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 23 Jan 2025 | 11,250 | 11,250 (0%) | 0% | 131.2 | 1,476,113 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 23 Jan 2025 | 11,250 | 0 (0%) | 0% | 275 | 3,093,750 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 23 Jan 2025 | 11,250 | 0 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 29 Feb 2024 | 30,000 | 30,000 (0%) | 0% | 59.3 | 1,777,500 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 29 Feb 2024 | 30,000 | 0 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 29 Feb 2024 | 13,557 | 3,438 (0%) | 0% | 151.4 | 2,052,937 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 29 Feb 2024 | 13,005 | 16,995 (0%) | 0% | 150.6 | 1,958,553 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 29 Feb 2024 | 1,906 | 617 (0%) | 0% | 153.6 | 292,800 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 29 Feb 2024 | 915 | 2,523 (0%) | 0% | 152.4 | 139,446 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 29 Feb 2024 | 516 | 0 (0%) | 0% | 156.5 | 80,775 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 29 Feb 2024 | 101 | 516 (0%) | 0% | 154.1 | 15,561 | Common Stock | |
| Vir biotech Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 12,054 | 12,054 | - | - | Stock Option (Right to Buy) | |
| Vir biotech Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 6,027 | 121,174 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 18 May 2023 | 3,454 | 3,454 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 15 Aug 2022 | 30,000 | 0 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 15 Aug 2022 | 30,000 | 30,000 (0%) | 0% | 30.1 | 902,700 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 15 Aug 2022 | 16,186 | 4,568 (0%) | 0% | 230.7 | 3,734,272 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 15 Aug 2022 | 11,600 | 20,754 (0%) | 0% | 229.9 | 2,667,188 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 15 Aug 2022 | 3,853 | 715 (0%) | 0% | 231.6 | 892,547 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 15 Aug 2022 | 3,670 | 33,670 (0%) | 0% | 63.9 | 234,366 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 15 Aug 2022 | 3,670 | 0 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 15 Aug 2022 | 1,218 | 32,354 (0%) | 0% | 228.3 | 278,106 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 15 Aug 2022 | 715 | 0 (0%) | 0% | 232.8 | 166,459 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 15 Aug 2022 | 98 | 33,572 (0%) | 0% | 226.2 | 22,164 | Common Stock | |
| Syros Pharmaceuticals Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Vir biotech Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2022 | 12,810 | 12,810 | - | - | Stock Option (Right to Buy) | |
| Vir biotech Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2022 | 6,405 | 115,147 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 18 May 2022 | 5,153 | 5,153 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharma Inc | Phillip A. Sharp | Director | 15 Jul 2021 | 4,032 | 4,032 | - | - | Stock Option (right to buy) | ||
| Syros Pharmaceuticals Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Vir biotech Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 6,748 | 6,748 | - | - | Stock Option (Right to Buy) | |
| Vir biotech Inc | Phillip A. Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 3,374 | 108,742 (0%) | 0% | 0 | Common Stock |